FILING ANALYSIS · TUESDAY, NOVEMBER 10
Arbutus Biopharma Corp ABUS — 8-K: Results of Operations and Financial Condition
neutral
Arbutus reported a strong financial position with $337.5M in cash and marketable securities, returned $230M to shareholders via a tender offer, and had the FDA lift the clinical hold on its oral PD-L1 inhibitor, AB-101. The company also expanded its international patent infringement enforcement against Pfizer and BioNTech.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →